ZBTB17

Across TCGA pan-cancer cohorts, ZBTB17 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZBTB17 data layer compared with 17 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher ZBTB17 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZBTB17 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

STAD, KIRP, and PRAD are the cancer types where ZBTB17 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	All	0.175	0.555	.023	18	view →
KIRP	DFS	Median	All	0.277	0.867	.004	6	view →
PRAD	DFS	Median	All	0.085	0.774	.001	6	view →
BLCA	OS	Median	All	0.188	0.687	.020	6	view →
UCEC	DFS	Median	All	0.997	0.890	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZBTB17–STAD (DFS)

Open the STAD breakdown →